Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
McKesson
Johnson and Johnson
AstraZeneca
Harvard Business School

Last Updated: June 26, 2022

CLINICAL TRIALS PROFILE FOR LOTENSIN HCT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Lotensin Hct

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00630708 ↗ Safety of Dual Blockage of Rennin-angiotensin System in Patients With Advanced Renal Insufficiency Terminated Nanfang Hospital of Southern Medical University N/A 2008-02-01 The primary aim of the present study is to assess the safety of combined treatment of benazepril (an ACE inhibitor) or losartan (an ARB) in non-diabetic patients with advanced renal insufficiency.
NCT00649038 ↗ Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg Completed Mylan Pharmaceuticals Phase 1 2002-12-01 The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fed conditions.
NCT00649597 ↗ Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg Completed Mylan Pharmaceuticals Phase 1 2002-11-01 The objective of this study was to investigate the bioequivalence of Mylan benazepril HCl and hydrochlorothiazide 20 mg/25 mg to Novartis Lotensin HCT® 20 mg/25 mg combination tablets following a single, oral 40 mg/50 mg (2 x 20 mg/25 mg) dose administration under fasting conditions.
NCT00836537 ↗ Benazepril HCl 40 mg Tablets, Fed Completed Teva Pharmaceuticals USA Phase 1 2001-03-01 This study will compare the relative bioavailability (rate and extent of absorption) of 40 mg Benazepril Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 40 mg LOTENSIN® Tablets by Novartis Pharmaceuticals following a single oral dose (1 x 40 mg) in healthy adult volunteers under non-fasting conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Lotensin Hct

Condition Name

Condition Name for Lotensin Hct
Intervention Trials
Healthy 4
Hypertension 3
Henoch-Schoenlein Purpura Nephritis 2
Hypotension on Induction 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Lotensin Hct
Intervention Trials
Purpura, Schoenlein-Henoch 3
Purpura 3
Nephritis 3
Hypertension 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lotensin Hct

Trials by Country

Trials by Country for Lotensin Hct
Location Trials
United States 7
China 4
Switzerland 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Lotensin Hct
Location Trials
North Dakota 3
Nebraska 1
North Carolina 1
California 1
Missouri 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lotensin Hct

Clinical Trial Phase

Clinical Trial Phase for Lotensin Hct
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Lotensin Hct
Clinical Trial Phase Trials
Completed 8
Recruiting 2
Terminated 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lotensin Hct

Sponsor Name

Sponsor Name for Lotensin Hct
Sponsor Trials
Mylan Pharmaceuticals 2
Teva Pharmaceuticals USA 2
Nanjing Children's Hospital 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Lotensin Hct
Sponsor Trials
Other 15
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Colorcon
Boehringer Ingelheim
Johnson and Johnson
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.